Nass M
Department of Internal Medicine, Parkview Hospital, Brunswick, Maine, USA.
Infect Dis Clin North Am. 1999 Mar;13(1):187-208, viii. doi: 10.1016/s0891-5520(05)70050-7.
Anthrax vaccine is being administered to all 2.4 million active duty, reserve, and National Guard troops, as prophylaxis against biologic warfare. The vaccine's effectiveness in this setting may be limited. This article discusses unresolved issues of safety, with an emphasis on the need for careful surveillance of vaccines used by the military, which has sidestepped the commercial process. Also considered are ethical issues related to the development and use of military biologics, as the United States Army advances its Joint Vaccine Acquisition Program, a plan to produce more than ten vaccines specifically for biologic warfare threat, and to administer them to all military servicemembers.
炭疽疫苗正被接种给所有240万现役、预备役和国民警卫队部队，作为预防生物战的措施。该疫苗在这种情况下的有效性可能有限。本文讨论了尚未解决的安全问题，重点强调了对军队使用的疫苗进行仔细监测的必要性，因为军队避开了商业流程。随着美国陆军推进其联合疫苗采购计划，即一项生产十多种专门针对生物战威胁的疫苗并将其接种给所有军人的计划，还考虑了与军事生物制剂的研发和使用相关的伦理问题。
